Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

Exclusion Criteria

• •Patients with a DSM-IV diagnosis of Delirium, Dementia, and Amnestic, and other Cognitive Disorders.
• •Patients who plan to produce a pregnancy within the next 6 months, or patients who are pregnant or nursing women.
• •Patients who have a history of non-response to two or more sufficient trials of antidepressant medication (as defined in Table 1).
• •Patients with a principal diagnosis meeting DSM-IV criteria for:
• •* Major Depressive Disorder, current
• •* Bipolar Disorder or cyclothymia .Schizophrenia, Delusional (Paranoid) Disorders and Psychotic Disorders not elsewhere classified.
• •* Anorexia Nervosa or Bulimia
• •Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence on any drug, including alcohol, excluding caffeine and tobacco.
• •Patients who have taken psychotropic medication or herbal preparations with putative psychotropic effects within 7 days prior to Visit 2. Patients taking a monoamine oxidase inhibitor (a type of antidepressant) (MAOI) must have a washout period of 14 days prior to visit 2, and patients taking fluoxetine must have a washout period of at least 4 weeks prior to Visit 2.
• •Patients who would pose a serious risk for suicide during the course of the study, as evidenced by one of the following:
• •* Report of having a specific plan for killing themselves
• •* A score of 3 or higher on the Hamilton Depression Rating Scale item #3 as rated by the treating clinician at Week 0, (indicative of active suicidal thoughts or behaviors)
• •* A suicide attempt within the past 12 months requiring emergency room visit, medical or psychiatric hospitalization, or otherwise deemed to be life-threatening (e.g. an overdose of \> 1 week's dose of medication.
• •Patients with unstable medical conditions, such as acute hyperthyroidism, uncorrected hypothyroidism, undiagnosed fever, uncontrolled angina, or any other serious medical illness, including any cardiovascular, hepatic, respiratory, hematological, endocrinologic o neurologic disease, or any clinically significant laboratory abnormality.
• •Patients who lack the capacity to proved informed consent
• •50% or greater decrease in HDRS total score from visit 2 to visit 3 or a CGI-Improvement score of 1 ("very much improved") or 2 ("much improved") at Visit 3
• •Patients receiving CGI Improvement scores of 6 ("much worse") or 7 ("very much worse") for two consecutive visits will be withdrawn from the study.
• •Patients who meet criteria for Major Depressive Disorder at any time during the course of the study will be withdrawn from the study.